Suchergebnisse - "Melemed, Allen"

PubPharm (54)

1

ACTION : a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma

enthalten in: Neuro-oncology | 2024

von Arrillaga-Romany, I. | Lassman, A. | McGovern, S. | +9

2

ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Arrillaga-Romany, I. | Gardner, S. | Odia, Y. | +27

3

PHARMACEUTICAL COMPOSITIONS AND USES THEREOF FOR THE TREATMENT OF GLIOMA

enthalten in: Europäisches Patentamt | 2024

von ALLEN JOSHUA EDWARD | MELEMED ALLEN | PRABHU VARUN VIJAY | +2

4

PHARMACEUTICAL COMPOSITIONS AND USES THEREOF FOR THE TREATMENT OF GLIOMA

enthalten in: Europäisches Patentamt | 2024

von ALLEN JOSHUA EDWARD | MELEMED ALLEN | PRABHU VARUN VIJAY | +2

5

Immunohistochemistry Detection of Histone H3 K27M Mutation in Human Glioma Tissue

enthalten in: Applied immunohistochemistry & molecular morphology : AIMM | 2024

von Tarapore, R. | Arain, S. | Blaine, E. | +3

6

Design and rationale of a randomized, double-blind, placebo-controlled, Phase 2/3 study to evaluate the safety and efficacy of dociparstat sodium (DSTAT) in adults with acute lung injury associated with severe COVID-19

enthalten in: ResearchSquare.com | 2022

von Lasky, J. | Fuloria, J. | Morrison, M. | +4

7

Design and rationale of a randomized, double-blind, placebo-controlled, Phase 2/3 study evaluating dociparstat in acute lung injury associated with severe COVID-19

enthalten in: ResearchSquare.com | 2022

von Lasky, J. | Fuloria, J. | Morrison, M. | +4

8

Modernizing Clinical Trial Eligibility Criteria : Recommendations of the ASCO-Friends of Cancer Research Performance Status Work Group

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2021

von Magnuson, A. | Bruinooge, S. | Singh, H. | +14

CommentIn: Clin Cancer Res. 2021 May 1;27(9):2369-2371. - PMID 33602680

9

Design and Rationale of a Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study Evaluating Dociparstat in Acute Lung Injury Associated with Severe COVID-19

enthalten in: Advances in therapy | 2021

von Lasky, J. | Fuloria, J. | Morrison, M. | +4

10

Design and Rationale of a Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study Evaluating Dociparstat in Acute Lung Injury Associated with Severe COVID-19

enthalten in: Advances in therapy | 2020

von Lasky, J. | Fuloria, J. | Morrison, M. | +4

1
2
3
4
5
6
Nächster »
[6]